Publicaciones científicas

/cun/investigacion/publicaciones-cientificas/areaMain/02
  • Obesity phenotypes and their paradoxical association with cardiovascular diseases

    Vecchié A (1), Dallegri F (2), Carbone F (1), Bonaventura A (1), Liberale L (3), Portincasa P (4), Frühbeck G (5), Montecucco F (6). (1) First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, Italy.
    (2) First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, Italy; Ospedale Policlinico San Martino, Istituto di Ricovero e Cura a Carattere Scientifico per l'Oncologia, 10 Largo Benzi, 16132 Genoa, Italy.
    (3) First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, Italy; Centre for Molecular Cardiology, University of Zürich, 12 Wagistrasse, 8952 Schlieren, Switzerland.
    (4) Clinica Medica "A. Murri", Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro" Medical School, Bari, Italy.
    (5) Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Spain; Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (6) First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, Italy; Ospedale Policlinico San Martino, Istituto di Ricovero e Cura a Carattere Scientifico per l'Oncologia, 10 Largo Benzi, 16132 Genoa, Italy; Centre of Excellence for Biomedical Research (CEBR), University of Genoa, 9 viale Benedetto XV, 16132 Genoa, Italy.

    European Journal of Internal Medicine 31 de OCTUBRE de 2017

  • Counting ovarian antral follicles by ultrasound: a practical guide

    Coelho Neto MA (1), Ludwin A (2), Borrell A (3), Benacerraf B (4), Dewailly D (5), da Silva Costa F (6), Condous G (7), Alcazar JL (8), Jokubkiene L (9), Guerriero S (10), Van den Bosch T (11), Martins WP (1,12). (1) Department of Obstetrics and Gynecology, Ribeirao Preto Medical School, Universtiy of São Paulo.
    (2) Department of Gynecology and Oncology, Jagiellonian University, Krakow, Poland.
    (3) BCNatal, Hospital Clinic Barcelona, Barcelona, Catalonia, Spain.
    (4) Department of Radiology and Obstetrics and Gynecology, Brigham and Women's Hospital, Harvard Medical School, Boston, United States of America.
    (5) CHU Lille, Department of Endocrine Gynecology and Reproductive Medicine, Hospital Jeanne de Flandre, F-59000, Lille, France.
    (6) Department of Obstetrics and Gynaecology, Monash University and Monash Ultrasound for Women, Melbourne, Victoria, Australia.
    (7) Department of Obstetrics and Gynaecology, Sydney Medical School, Nepean, University of Sydney, Sydney, Australia.
    (8) Department of Obstetrics and Gynecology, Clinica Universidad de Navarra, School of Medicine, University of Navarra, Pamplona, Spain.
    (9) Department of Obstetrics and Gynecology, Skåne University Hospital, Malmo, Sweden.
    (10) Department of Obstetrics and Gynecology, University of Cagliari, Cagliari, Italy.
    (11) Department of Obstetrics & Gynecology, University Hospitals K.U. Leuven, Leuven, Belgium.
    (12) SEMEAR fertilidade, Reproductive Medicine, Ribeirão Preto, Brazil.

    Ultrasound in Obstetrics & Gynecology 28 de OCTUBRE de 2017

  • Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma Newly Diagnosed in Pediatric Patients

    Tejada S (1), Alonso M (2), Patiño A (2), Fueyo J (3), Gomez-Manzano C (3), Diez-Valle R (4). (1) Department of Neurosurgery, Clínica Universidad de Navarra (CUN), Pamplona, Spain.
    (2) Department of Pediatrics, Program of Solid Tumors, Center for the Applied Medical Research at University of Navarra, Pamplona, Spain.
    (3) Department of Neuro-Oncology, MD Anderson Cancer Center, Houston, Texas.
    (4) Neurosurgical Department, Clínica Universidad de Navarra (CUN), Pamplona, Spain.

    Neurosurgery 27 de OCTUBRE de 2017

  • Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients

    Avet-Loiseau H (1), Bahlis NJ (2), Chng WJ (3), Masszi T (4), Viterbo L (5), Pour L (6), Ganly P (7), Palumbo A (8), Cavo M (9), Langer C (10), Pluta A (11), Nagler A (12), Kumar S (13), Ben-Yehuda D (14), Rajkumar SV (13), San-Miguel J (15), Berg D (16), Lin J (16), van de Velde H (16), Esseltine DL (16), di Bacco A (16), Moreau P (17), Richardson PG (18). (1) University Cancer Center of Toulouse Institut National de la Sante, Toulouse, France
    (2) Southern Alberta Cancer Research Institute, University of Calgary, Calgary, AB, Canada.
    (3) National University Cancer Institute, Singapore, Singapore.
    (4) St. Istvan, St. Laszlo Hospital, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary.
    (5) Instituto Portugues de Oncologia do Porto Francisco Gentil, Entidade Publica Empresarial (IPOPFG, EPE), Porto, Portugal.
    (6) University Hospital Brno, Brno, Czech Republic.
    (7) Department of Haematology, Christchurch Hospital, Christchurch, New Zealand.
    (8) Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria (AOU) S. Giovanni Battista, Torino, Italy.
    (9) University of Bologna, Bologna, Italy.
    (10) University Hospital of Ulm, Ulm, Germany.
    (11) Dept of Hematological Oncology, Oncology Spec. Hospital, Brzozow, Poland.
    (12) Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel.
    (13) Mayo Clinic, Rochester, MN, United States.
    (14) Hadassah Medical Center, Kiryat Hadassah, Jerusalem, Israel.
    (15) Clinica Universidad de Navarra, Centro Investigacion Medica Aplicada (CIMA), IDISNA, CIBERONC, Pamplona, Spain.
    (16) Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, United States.
    (17) University Hospital Hotel Dieu, Nantes, France.
    (18) Dana-Farber Cancer Institute, Boston, MA, United States.

    Blood 20 de OCTUBRE de 2017

  • Theta-phase closed-loop stimulation induces motor paradoxical responses in the rat model of Parkinson disease

    Cordon I (1), Nicolás MJ (1), Arrieta S ()1, Alegre M (2), Artieda J (3), Valencia M (4). (1) Neuroscience Program, Center for Applied Medical Research, University of Navarra, 31008 Pamplona, Spain; Navarra Institute for Health Research, 31008 Pamplona, Spain.
    (2) Neuroscience Program, Center for Applied Medical Research, University of Navarra, 31008 Pamplona, Spain; Navarra Institute for Health Research, 31008 Pamplona, Spain; Neurophysiology Service, Clínica Universidad de Navarra, University of Navarra, 31008 Pamplona, Spain.
    (3) Neuroscience Program, Center for Applied Medical Research, University of Navarra, 31008 Pamplona, Spain; Navarra Institute for Health Research, 31008 Pamplona, Spain; Neurophysiology Service, Clínica Universidad de Navarra, University of Navarra, 31008 Pamplona, Spain.
    (4) Neuroscience Program, Center for Applied Medical Research, University of Navarra, 31008 Pamplona, Spain; Navarra Institute for Health Research, 31008 Pamplona, Spain.

    Brain Stimulation 13 de OCTUBRE de 2017

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra